SPL026
DrugIntravenous
Other names: N,N-dimethyltryptamine, DMT
NCT Number: NCT05553691
The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Mac Clinical Research, Manchester, Greater Manchester, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous
Other names: N,N-dimethyltryptamine, DMT
Time frame: Screening to End-of-Study Follow-up (Day 29)
Adverse events (AEs)
Time frame: Screening, Day -1 and Day 1
Values of potential clinical importance
Time frame: Screening to Day 2
Heart rate
Time frame: Screening to Day 2
Blood pressure
Time frame: Screening to Day 2
Temperature
Time frame: Screening to Day 2
QTcX intervals
Time frame: Screening to End-of-Study Follow-up (Day 29)
Columbia-Suicide Severity Rating Scale
Time frame: 2, 5, 7, 10, 11, 13, 15, 30, 60, 120, 240 minutes post-dose
Pharmacokinetic parameter calculation in the Test Cohort compared to the Control Cohort
Time frame: Day 1 (dosing day)
MEQ in the Test Cohort compared to the Control Cohort
Time frame: Day 1 (dosing day)
CEQ in the Test Cohort compared to the Control Cohort
Time frame: Day -1 and Day 29
RRS in the Test Cohort compared to the Control Cohort
Time frame: Day -1, Day 15 and Day 29
WEMWBS in the Test Cohort compared to the Control Cohort
Time frame: Day -1, Day 8, Day 15 and Day 29
MADRS in the Test Cohort compared to the Control Cohort
Small Pharma Ltd
Industry
An Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Exploratory Efficacy of Intravenous SPL026 Drug Product (DMT Fumarate) Alone or in Combination With SSRIs in Patients With Major Depressive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial Details